dc cell

Bisoprolol, a selective beta-1 adrenergic receptor antagonist, selectively and competitively binds to and blocks beta-1 adrenergic receptors in the heart, thereby with antihypertensive activity and devoid of intrinsic sympathomimetic activity.

DC-5163 is a potent inhibitor of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) with IC50 of 176.3 nM and Kd of 3.192 μM. DC-5163 selectively inhibits cancer cell proliferation and induces apoptosis, and partially inhibits the glycolysis pathway.

PROTAC FGFR2 degrader 1 (compound N5) is a potent PROTAC that efficiently targets FGFR2, boasting a DC 50 value of 6.46 nM and an FGFR2 IC 50 of 0.08 nM. This compound exhibits significant anti-proliferative effects and high selectivity. It induces G0 G1 arrest in the cell cycles of KATOIII and SNU16 and inhibits apoptosis by diminishing the activation of p-ERK and p-PLCγ, the downstream proteins of FGFR2. Additionally, PROTAC FGFR2 degrader 1 maintains over 50% inhibition of gastric cancer cells at a concentration of 0.17 nM and effectively suppresses the growth of SNU16 xenograft tumors in a mouse model.

Bisoprolol is a cardioselective β1-adrenergic blocker used for secondary prevention of heart failure, myocardial, angina pectorisinfarction (MI) and mild to moderate hypertension.

DC-CPin711, a potent and selective inhibitor of the bromodomain of CREB-binding protein (CBP) with an IC50 of 0.0626 μM, effectively halts the cell cycle at the G1 phase and promotes apoptosis [1].

HPK1-IN-28, a potent inhibitor of HPK1, enhances anti-tumor immunity in humans and demonstrates research potential in immune-related diseases, particularly tumors, by acting as a negative regulator of dendritic cell (DC), T-cell, and B-cell activation responses.

PROTAC STAT3 degrader-2 is a selective and effective PROTAC degrader of the STAT3 protein, exhibiting a DC50 of 3.54 μM in Molm-16 cells. It holds potential for cancer research [1].

N4-Benzoyl-2′-deoxycytidine is a synthetic nucleoside analog of the natural nucleoside deoxycytidine (dC), a competitive inhibitor of DNA polymerase. In vitro studies have shown that it inhibits replication in viruses, bacteria and eukaryotic cells. It has also been shown to inhibit tumor cell growth in animal models.

DC 432, a potent peptidomimetic inhibitor of N-terminal methyltransferase 1 2 (NTMT1 2) with an IC50 value of 54 nM, incorporates a BM30 peptide enhanced by five arginine residues. It effectively reduces the N-terminal methylation level of the regulator of chromosome condensation 1 and SET proteins in HCT116 cells, demonstrating cell permeability.

4-CF3-TPP-DC is an inert mitochondriotropic carrier that does not induce mitochondrial depolarization or cell death in C2C12 cells.

ML-T7, a powerful inhibitor of Tim-3, effectively disrupts its interactions with PtdSer and CEACAM1. This compound enhances the antitumor activity of adoptive transfer therapy involving cytotoxic T lymphocytes (CTLs) and CAR T cells, while also boosting T cell effector functions. Additionally, ML-T7 augments the killing activity of NK cells against tumor cells and improves the antigen-presenting capacity of dendritic cells (DCs). Demonstrating antitumor efficacy in preclinical models, ML-T7 shows potential either as a standalone treatment or in combination with Nivolumab for tumor immunotherapy research [1].

Ganoderic acid DM is an antiandrogenic osteoclastogenesis inhibitor, it especially suppresses the expression of c-Fos and nuclear factor of activated T cells c1 (NFATc1), this suppression leads to the inhibition of dendritic cell-specific transmembrane pr